Subtype
Thyroid Gland Carcinoma
CI-CAN-00006937THCAExplore in graph →
96 active trials8 approved drugs53 evidence items
- NCIt
- C4815
- DOID
- 3963
- Other
- 1 more code
Loading cancer entity…
Subtype
CI-CAN-00006937THCAExplore in graph →
Clinical trials
389 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04467021 | Cancer and Blood Pressure Management, CARISMA Study | active not recruiting | N/A | 61 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 16, 2026 | clinicaltrials |
| NCT01704586 |
| I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer(CLERAD-PROBE) |
| active not recruiting |
| N/A |
| 340 |
| University of WuerzburgOTHER |
| 1 |
| May 12, 2026 |
| clinicaltrials |
| NCT06271044 | a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS | active not recruiting | N/A | 61 | Helsinki University Central HospitalOTHER | 0 | Feb 21, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials